Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 13 Urinary Bladder Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Glioblastoma 1 Genomic Instability 1 Carcinoma, Hepatocellular 1 Biliary Tract Neoplasms 1 Advanced Unresectable or Metastatic Solid Malignancy 1 Adenocarcinoma of Lung 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1 ALK Gene Rearrangement Positive 1

Interventions

atezolizumab 1 alectinib 1 Vemurafenib 1 Fruit 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Genomic Instability × alectinib × Clear all

NCT02314481 2026-05-04

DARWINII

University College, London

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡